Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Aeglea Bio Therapeutics Inc    AGLE

AEGLEA BIO THERAPEUTICS INC (AGLE)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/16/2018 07/17/2018 07/18/2018 07/19/2018 07/20/2018 Date
9.14(c) 9.04(c) 9.36(c) 9.31(c) 9.2(c) Last
214 199 200 723 246 832 132 318 152 604 Volume
+4.10% -1.09% +3.54% -0.53% -1.18% Change
More quotes
Financials (USD)
Sales 2018 5,46 M
EBIT 2018 -32,9 M
Net income 2018 -31,7 M
Finance 2018 38,7 M
Yield 2018 -
Sales 2019 2,35 M
EBIT 2019 -40,4 M
Net income 2019 -45,8 M
Finance 2019 74,0 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 30,2x
EV / Sales2019 55,1x
Capitalization 204 M
More Financials
Company
Aeglea Biotherapeutics, Inc. is a clinical-stage biotechnology company, which engages in the design and development of human enzyme therapeutics for patients with rare genetic diseases and cancer.It develops pegzilarginase, its lead investigational therapy, for the treatment of Arginase 1... 
More about the company
Surperformance© ratings of Aeglea Bio Therapeutics In
Trading Rating : Investor Rating :
More Ratings
Latest news on AEGLEA BIO THERAPEUTICS IN
07/20AEGLEA BIO THERAPEUTICS : BioTherapeutics Appoints Dr. Anthony G. Quinn as Presi..
AQ
07/19Aeglea BioTherapeutics Appoints Dr. Anthony G. Quinn as President and Chief E..
GL
07/17AEGLEA BIO THERAPEUTICS : BioTherapeutics Appoints Dr. Bryan Lawlis to Board of ..
AQ
07/16Aeglea BioTherapeutics Appoints Dr. Bryan Lawlis to Board of Directors
GL
06/30AEGLEA BIO THERAPEUTICS : BioTherapeutics Reports Inducement Grants Under Nasdaq..
AQ
06/29Aeglea BioTherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 56..
GL
06/08AEGLEA BIOTHERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holde..
AQ
05/15AEGLEA BIO THERAPEUTICS : BioTherapeutics to Present at UBS Global Healthcare Co..
AQ
05/08AEGLEA : 1Q Earnings Snapshot
AQ
05/08AEGLEA BIO THERAPEUTICS : BIOTHERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANAL..
AQ
More news
Sector news : Bio Therapeutic Drugs
07/19Novartis, MorphoSys and Galapagos Shares Rise on News of Deal
DJ
07/09LONZA : restates 2017 figures after changing accounting standard
RE
07/03Sanofi beefs up diabetes pipeline to retrieve success
RE
06/29European stocks shrug off trade worries with quarterly gain
RE
06/29GILEAD SCIENCES : Rival Novartis, Gilead CAR-T therapies win European panel reco..
RE
More sector news : Bio Therapeutic Drugs
Latest Tweets
07/19Aeglea BioTherapeutics $AGLE Appoints Dr. Anthony G. Quinn as President and C.. 
07/17$AGLE BIOTHERAPEUTICS ... Daily Insider Ratings Report: July 16, 2018: Insid.. 
07/16Aeglea BioTherapeutics $AGLE Appoints Dr. Bryan Lawlis to Board of Directors .. 
07/13Our Friends in Berlin by Anthony Quinn review – life during wartime
16
07/07Get the latest news and updates for $SR $ABIL $AGLE $SAGE $VITC automatically..
1
More tweets
Qtime:114
News from SeekingAlpha
07/19New chief at Aeglea Bio 
07/09Rubius Therapeutics Proposes Terms For $200 Million IPO 
06/16A High-Throughput Screen For Cancer Stocks That Have Few (Or No) Fundamentals 
06/01HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am (06/01/2018) 
05/30After Hours Gainers / Losers (05/30/2018) 
Chart AEGLEA BIO THERAPEUTICS IN
Duration : Period :
Aeglea Bio Therapeutics In Technical Analysis Chart | AGLE | US00773J1034 | 4-Traders
Technical analysis trends AEGLEA BIO THERAPEUTICS IN
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 21,3 $
Spread / Average Target 132%
EPS Revisions
Managers
NameTitle
Anthony G. Quinn Chief Executive Officer & Director
Armen B. Shanafelt Chairman
Charles N. York Chief Financial Officer & Vice President
James Wooldridge Chief Medical Officer
George Georgiou Director
Sector and Competitors
1st jan.Capitalization (M$)
AEGLEA BIO THERAPEUTICS INC70.06%204
GILEAD SCIENCES8.00%100 185
VERTEX PHARMACEUTICALS18.38%45 900
REGENERON PHARMACEUTICALS-2.35%38 962
GENMAB9.33%10 874
NEUROCRINE BIOSCIENCES, INC.33.30%9 332